64 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
Jagiellonian University Medical College
NTS2-selective neurotensin mimetics with tetrahydrofuran amino acids.
University of Regensburg
Mimicking of Arginine by Functionalized N(¿)-Carbamoylated Arginine As a New Broadly Applicable Approach to Labeled Bioactive Peptides: High Affinity Angiotensin, Neuropeptide Y, Neuropeptide FF, and Neurotensin Receptor Ligands As Examples.
University of Regensburg
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Jagiellonian University Medical College
Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues.
University of Montpellier
The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.
Rti International
The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1).
The Scripps Research Institute
Identification of N-{[6-chloro-4-(2,6-dimethoxyphenyl)quinazolin-2-yl]carbonyl}-l-leucine (NTRC-808), a novel nonpeptide chemotype selective for the neurotensin receptor type 2.
Research Triangle Institute
Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.
Novartis Institutes For Biomedical Research
Identification of N-[(5-{[(4-methylphenyl)sulfonyl]amino}-3-(trifluoroacetyl)-1H-indol-1-yl)acetyl]-l-leucine (NTRC-824), a neurotensin-like nonpeptide compound selective for the neurotensin receptor type 2.
Research Triangle Institute
Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.
Research Triangle Institute
Imidazole-derived agonists for the neurotensin 1 receptor.
Sanford-Burnham Medical Research Institute
Synthesis and evaluation of a (18)F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors.
Friedrich-Alexander University
Discovery of ML314, a Brain Penetrant Non-Peptidicβ-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.
Sanford-Burnham Medical Research Institute
The synthesis of neurotensin antagonist SR 48692 for prostate cancer research.
Durham University
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
Institute of Organic Synthesis
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
University of Siena
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
H. Lundbeck
Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensin receptor 1.
Friedrich-Alexander University
Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
Friedrich-Alexander University
Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
National Center For Scientific Research Demokritos
Evaluation of lactam-bridged neurotensin analogues adjusting psi(Pro10) close to the experimentally derived bioactive conformation of NT(8-13).
Friedrich-Alexander University
In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.
Medical University of South Carolina
Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors.
Washington University
Ketomethylene and (cyanomethylene)amino pseudopeptide analogues of the C-terminal hexapeptide of neurotensin.
Instituto De Qu£Mica M£Dica (Csic)
Neurotensin receptor binding and antinociceptive activity for lipophilic N-amido neurotensin(913) analogs
TBA
Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics.
Friedrich-Alexander University
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Università
Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic.
Medical University of South Carolina Campus
Synthesis of neurotensin(8-13)-phosphopeptide heterodimers via click chemistry.
Institute of Radiopharmacy
The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach.
Wyeth Research
Stable isosteres of neurotensin c-terminal pentapeptides derived by modification of the amide function
TBA
A structure-affinity study of the amino acid side-chains in neurotensin : N and C terminal deletions and Ala-scan
TBA
Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy.
Medical University of South Carolina
Synthesis and applications of polyamine amino acid residues: improving the bioactivity of an analgesic neuropeptide, neurotensin.
University of Utah
The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.
Research Triangle Institute
Neurotensin(8-13) analogs as dual NTS1 and NTS2 receptor ligands with enhanced effects on a mouse model of Parkinson's disease.
University of Bonn
Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors.
Friedrich-Alexander Universit£T Erlangen-N£Rnberg
Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic.
University of Sherbrooke
Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies.
Vrije Universiteit Brussel
Hormone-like conopeptides - new tools for pharmaceutical design.
University of Queensland
Synthesis of neurotensin(9-13) analogues exhibiting enhanced human neurotensin receptor binding affinities.
Medical University of South Carolina
Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.
Sanford Burnham Prebys Medical Discovery Institute
Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor.
University of Nebraska Medical Center
An Alkyne-functionalized Arginine for Solid-Phase Synthesis Enabling "Bioorthogonal" Peptide Conjugation.
University of Regensburg
Fluorescence Labeling of Neurotensin(8-13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity.
University of Regensburg
Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS
University of Regensburg
In Search of the Optimal Macrocyclization Site for Neurotensin.
University of Sherbrooke
Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13).
University of Sherbrooke
Identification and biological evaluation of thiazole-based inverse agonists of RORγt.
Phenex Pharmaceuticals
Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues.
University of Montpellier
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins
Incyte
Prodrugs of cytotoxic active agents having enzymatically cleavable groups
Bayer Aktiengesellschaft